Aventa FusionPlus is a next-generation sequencing test designed to identify translocations, gene fusions, and rearrangements across 361 genes from formalin-fixed, paraffin embedded tumour tissue
Aventa Genomics has launched the Aventa FusionPlus clinical test. (Credit: Michal Jarmoluk from Pixabay)
Aventa Genomics, a clinical laboratory joint venture between Arima Genomics and US-based Protean BioDiagnostics, has rolled out its first 3D genomics clinical test dubbed Aventa FusionPlus, for patients with solid cancers.
Aventa FusionPlus is a laboratory-developed next-generation sequencing (NGS) test.
It is designed to identify translocations, gene fusions, and rearrangements across 361 genes from formalin-fixed, paraffin embedded (FFPE) tumour tissue.
The NGS test is based on 3D genomics technology that allows for a 100–1000-fold signal amplification, the detection of novel breakpoints and fusion partners, and the preservation of the spatial proximity of fused and rearranged genes.
Aventa Genomics executive director Chris Roberts said: “In previously characterised tumor specimens from patients with no known actionable driver, the Aventa FusionPlus test detected potentially actionable variants in half of the cases.
“The increase in diagnostic yield from detecting actionable biomarkers FISH and RNA sequencing miss, we believe, will provide more treatment options and will facilitate improved patient management.”
According to the clinical laboratory, the test can detect actionable biomarkers that standard testing techniques like fluorescent in situ hybridisation (FISH) and RNA sequencing can identify but also reveal those that are missing.
Aventa FusionPlus also makes use of proprietary analysis and reporting platforms to provide a thorough evaluation of the malignancy.
Arima Genomics CEO Sid Selvaraj said: “This first clinical application of 3D genomics marks a significant milestone in our journey from enabling genomic discoveries to now assisting patient diagnosis and therapy selection.
“We thank Protean BioDiagnostics for this joint venture, and we believe that this is only the beginning for the use of 3D genomics technology in the clinical space.”
Aventa Genomics is engaged in the development of 3D genomics tools to detect targets that can be drugged and resolve diagnostic problems. Its testing service is conducted in the company’s CLIA-certified lab in Orlando, Florida.
Protean BioDiagnostics supports pharmaceutical and biotech companies in developing clinical assays and companion diagnostics from its CLIA-certified, CAP-accredited laboratory in Orlando. Arima Genomics, on the other hand, is engaged in providing genomic insights.